- Pinkfong's hit series "Pinkfong Wonderstar" expands with its first spin-off special focusing on Hogi
- The mini-movie is set to captivate audiences worldwide exclusively on Netflix on November 3
Click HERE for Trailer and HERE for Stills
SEOUL, South Korea, Oct. 31, 2024 /PRNewswire/ -- The Pinkfong Company, the global entertainment company behind Baby Shark, announces today the global release of "Pinkfong & Hogi Mini-Movie: The Tricky Three Cars," a special adventure mini-movie based on the globally beloved YouTube Originals TV series "Pinkfong Wonderstar". The 40-minute action-packed adventure debuts on Netflix worldwide on Sunday, November 3 at 11am ET in both English and Korean dubbed versions.
This exciting spin-off showcases Hogi in his first starring role, Pinkfong's best friend who has already captured the hearts of over 10 million YouTube subscribers globally. The mini-movie follows Hogi as he embarks on a mission to rescue Pinkfong and their friends from the Tricky Three Cars, a mysterious trio who have invaded the peaceful town of Wonderville.
"We are thrilled to bring "Pinkfong & Hogi Mini-Movie: The Tricky Three Cars" to a global audience on Netflix," said Gemma Joo, Chief Business Officer of The Pinkfong Company. "This special showcases Hogi in his first starring role and expands the beloved Pinkfong universe. We can't wait for fans around the world to join Hogi on this heart-racing adventure that celebrates courage and friendship".
Supervised by The Pinkfong Company's External Director Shaun Kim, a former Lead Layout Artist at Pixar Animation Studios, the mini-movie features dazzling animation and visual effects that transport viewers into the fantastic world of Wonderville.
Following its release in South Korea, the mini-movie quickly climbed to the #1 spot in Netflix's Top 10 Kids Movies category in the country, maintaining a position in the Top 10 for an impressive 50 days, according to FlixPatrol.
The mini-movie introduces Hogi as a 'super shy' introverted hero, embarking on a thrilling journey to discover true courage and friendship. Audiences will be captivated by the engaging story that not only highlights Hogi's personal growth but also reinforces the strong bonds of friendship among the beloved characters of Wonderville, including Pinkfong, Jeni, Poki, and Rachel.
Fans can also look forward to other highly anticipated content to be released alongside "Pinkfong & Hogi Mini-Movie: The Tricky Three Cars", including "Bebefinn Dance Time" and "Pinkfong Little Dino School". "Bebefinn Dance Time will be available in seven languages including English, Spanish and Korean, while Pinking Little Dino School will be available in English and Korean dubbed versions. Both will be available worldwide on November 3.
About The Pinkfong Company
The Pinkfong Company is a global entertainment company that delivers content and entertaining experiences around the world. Driven by award-winning brands and IPs, the company has created and distributed a range of content across genres and formats including original animated series, world live tours, interactive games, and more. Believing in the power of entertaining and engaging content, The Pinkfong Company is committed to connecting people around the world and bringing joy and inspiration to worldwide audiences of all ages. For more information, please visit the website or follow the company on LinkedIn.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
"Pinkfong & Hogi Mini Movie: The Tricky Three Cars" to Premiere Globally on Netflix
SINGAPORE, June 5, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facility will be the Company's key DP facility designed to meet the latest and most stringent requirements for international markets, with expected output of approximately 100 million units of pre-filled syringes and vials per year.
Located on a 13.5-hectare site in Tuas Biomedical Park, the Hub will be the first of its kind in Singapore, built on WuXi Biologics' proprietary technology platforms and industry-leading capabilities to offer dual sourcing solutions for biopharmaceutical companies worldwide. The Hub will add 120,000 liters of manufacturing capacity to the Company's global network, reinforcing Singapore's position as a leading biopharmaceutical hub. On this site, WuXi Biologics' subsidiary WuXi XDC achieved mechanical completion of its Singapore ADC production site in 2025.
Spanning approximately 30,000 square meters, the modular DP facility will feature advanced manufacturing lines, centralized Quality Control (QC) labs for full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, significantly expanding the Company's end-to-end DP capabilities. With three pre-filled syringe (PFS) lines and two vial lines for liquid and lyophilized products, it will deliver integrated DP manufacturing for multiple dosage forms across clinical and commercial stages. The facility will also incorporate green technologies, including solar panels and an advanced system for energy monitoring and analysis, reflecting WuXi Biologics' commitment to sustainability. Operations are expected to commence in 2027.
Dr. Chris Chen, CEO of WuXi Biologics, said, "We are excited to celebrate another major milestone for our Singapore CRDMO hub. This achievement further reinforces our ability to provide global biopharmaceutical companies with a resilient and geographically diversified supply chain, one built on our world-class quality systems, cutting-edge innovation, and operational excellence. At the same time, we are dedicated to contributing to the local community in Singapore and the long-term development of its biopharmaceutical industry."
Construction across the Singapore CRDMO hub continues to advance, with the drug substance facility currently in the design phase. The Hub marks a significant step in WuXi Biologics' global extension and its long-term commitment as the partner of choice for global biopharmaceutical companies.
WuXi Biologics' global manufacturing footprint spans China, the United States, Ireland, Germany, and Singapore, with 24 drug substance (DS) facilities and 18 drug product (DP) facilities currently in operation. This network provides integrated dual-sourcing solutions spanning DS and DP, from clinical development through commercial-scale manufacturing. As of 2025, WuXi Biologics had successfully passed 46 regulatory inspections worldwide, including 22 conducted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), achieving a 100% success rate with no critical findings and no data integrity issues.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs)
The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
